ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Improved prognostic stratification with the FIGO 2023 endometrial cancer staging system. A multicenter Spanish cohort study.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of applying the FIGO 2023 staging system compared with FIGO 2009 in a real-world cohort of patients with early-stage endometrial cancer who underwent surgery. STUDY DESIGN/
methodsThis multicenter retrospective cohort study included patients with apparent early-stage endometrial cancer diagnosed between 2000 and 2020 across 18 Spanish centers. All patients underwent primary surgery and were classified according to both FIGO 2009 and FIGO 2023 criteria. Stage migration was assessed, and the characteristics of newly defined subgroups were described. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were compared between classifications.
resultsA total of 4566 patients were included. Application of the FIGO 2023 system resulted in stage migration in 909 patients (19.9%) compared with FIGO 2009. The FIGO 2023 system showed a higher 5-year OS for Stage I patients than the 2009 classification (91.3% vs. 88.2%). Within the new substages, 5-year OS was 93.9% in Stage IA1 and 91.9% in Stage IA2, and Stage IA3 demonstrated distinct survival outcomes. Overall survival for Stage III remained comparable between classifications, although outcomes varied across subcategories. In a simplified classification (Stages I-III), the FIGO 2023 system showed improved prognostic discrimination for both PFS and OS according to Harrell's C-index.
conclusionsThe FIGO 2023 staging system leads to substantial reclassification of early-stage endometrial cancer patients and introduces new prognostic subgroups. This increased granularity improves prognostic stratification and may support individualized treatment decisions, even when molecular testing is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.